In DDLPS animal models, selinexor and doxorubicin as single agents induced a tumor growth delay which was more pronounced for the XPO1 inhibitor than the anthracycline in all PDXs (maximum TVI%: 46–80 % vs. 37–60 %) (Fig. 3a; Table 1). The gene discussed is XPO1; the disease is neoplasm.